Takeda announces Paradigm shift

Published: 13-Mar-2007
Media

Takeda Pharmaceutical Company is to acquire Paradigm Therapeutics, after Paradigm\'s shareholders agreed on 12 March to the move.


Takeda Pharmaceutical Company is to acquire Paradigm Therapeutics, after Paradigm's shareholders agreed on 12 March to the move.

Financial terms were not disclosed. Subject to completion, which is expected to occur within a few weeks, Paradigm will become a subsidiary of Takeda Europe Holdings, a wholly owned subsidiary of Takeda. Paradigm will be renamed Takeda Cambridge, and Paradigm's subsidiary in Singapore will be renamed Takeda Singapore.

Founded in 1999 by University of Cambridge researchers, Paradigm has established target identification and validation capabilities based on genetic engineering and in vivo pharmacology. The British firm has also developed a pipeline of novel drug discovery targets and compounds in key areas of unmet medical need including pain, CNS disorders, prostate and breast cancer, diabetes, hyperlipidemia, and obesity.

Following the merger, which builds upon the two companies' 2005 therapeutic area alliance, Paradigm's technologies and researchers will be integrated into Takeda and will help to speed up a number of projects.

  • Companies:
  • Takeda
See more

You may also like

Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

Read more
The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases

Trending Articles

  1. Hovione sells iMAX business Hovione has concluded the sale of all of the share capital of iMAX Diagnostic Imaging
  2. Lonza breaks ground on second manufacturing facility in Singapore <p>Lonza Group and Bio*One Capital, a dedicated biomedical sciences investment management company in Asia, have broken ground on their large-scale commercial mammalian cell culture manufacturing facility at Tuas Biomedical Park in Singapore.</p>
  3. IDT Biologika establishes new US base <p>IDT Biologika has opened new offices in Herndon, Virginia to serve pharmaceutical and biopharmaceutical customers in the US. It will be run by Peter Linzmeyer, executive vice president of IDT Biologika Corporation, a wholly owned subsidiary of IDT Biologika in Germany. </p>
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Transform and grow: manufacturing excellence in specialty chemicals With access to diverse end markets such as construction, automotive, electronics and agriculture, the ubiquitous specialty chemicals industry looks to be in great shape
  5. Trends and opportunities in biopharmaceutical product development and manufacturing The biopharmaceutical industry and its bioprocessing sector are healthy and continue to grow in size/revenue, breadth, importance and diversity. Worldwide sales of biopharmaceuticals are now more than $300 billion, increasing at an annual rate of about 12% annually. This growth has been relatively consistent during the past 15+ years, which is why the segment is attractive to investors, explains Eric Langer, President and Managing Partner, BioPlan Associates

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Media

Only a handful of pharma companies are developing the urgently needed new medicines for the poor

The development of new medical products that are considered the highest priority for people in developing countries is highly concentrated – among five pharmaceutical companies and on five diseases
Media

Takeda shows significant profit dip in Q1

Takeda will be looking to Shire’s drug pipeline to bolster future sales after disappointing Q1 results, says GlobalData
Media

GlobalData publishes analysis of top 25 global pharma companies

The data and analytics company has tracked the market cap performance of the top 25 pharma companies for the quarter ending 31 March, 2018 compared to 2017 revealing a number of interesting insights
Media

GlobalData names top 25 global pharma companies by market cap

The performance highlights of the top 25 publicly traded global pharma companies for the year 2017 have been confirmed in the latest research from GlobalData
Media

Takeda expands into Brazil

<p>Japan\'s largest drugmaker, Takeda Pharmaceutical Company, is to set up a subsidiary in Brazil. </p>
Media

Takeda to integrate Irish manufacturing operations

<p>Japanese pharmaceutical company Takeda Pharmaceutical is to integrate its subsidiaries Takeda Ireland (TIL) in Kilruddery and Takeda Pharma Ireland (TPI) in Dublin into a single operation on 1 July. All TPI assets will be transferred to TIL and TPI will be liquidated.</p>
Media

Takeda to acquire Millennium for US$8.8bn

<p>Takeda Pharmaceutical Company, of Japan, has signed a definitive agreement to purchase US biopharmaceutical company Millennium Pharmaceuticals for approximately US$8.8bn (Euro 5.53bn).</p>
Subscribe now